BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ICP-490 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ICP-490\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06845241-3427@assetmemo.bio
DTSTAMP:20261121T005833Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:ICP-490: Phase 1/2 readout est. (NCT06845241)
DESCRIPTION:ICP-490\, phase 1/2.\nStudy: Evaluate the Safety\, Tolerability
 \, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hod
 gkin Lymphoma\nEstimated primary completion: July 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/icp-490#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06845241
URL:https://assetmemo.bio/drug/icp-490#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
